Founded at the University of Cambridge, CardiaTec is developing a target discovery platform that uses AI to analyse large-scale cardiovascular data. “Despite the prevalence of cardiovascular ailments, there has been significant under-investment, so we believe these funds will provide CardiaTec with the opportunity to unearth treatments that make a real difference to patients.”Other participants in the funding round included Crista Galli Ventures, o2h ventures and Cambridge Enterprise.